Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis
ZC Gu, AH Wei, C Zhang, XH Wang, L Zhang… - Clinical …, 2020 - Elsevier
Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …
Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: A systematic review and meta-analysis
MF Dai, WX Xin, S Kong, HY Ding, L Fang - Thrombosis research, 2023 - Elsevier
Background The effect of extended thromboprophylaxis in improving the prognosis of adult
patients with coronavirus disease 2019 (COVID-19) after discharge remains debatable. This …
patients with coronavirus disease 2019 (COVID-19) after discharge remains debatable. This …
The use of oral anticoagulation is not associated with a reduced risk of mortality in patients with covid-19: a systematic review and meta-analysis of cohort studies
MF Dai, ST Guo, YJ Ke, BY Wang, F Yu, H Xu… - Frontiers in …, 2022 - frontiersin.org
Background: Hypercoagulability and thromboembolic events are associated with poor
prognosis in coronavirus disease 2019 (COVID-19) patients. Whether chronic oral …
prognosis in coronavirus disease 2019 (COVID-19) patients. Whether chronic oral …
No inexplicable disagreements between real-world data–based nonrandomized controlled studies and randomized controlled trials were found
Objectives We assessed disagreements between nonrandomized controlled studies based
on real-world data (NRCS-RWDs) and randomized controlled trials (RCTs). Study Design …
on real-world data (NRCS-RWDs) and randomized controlled trials (RCTs). Study Design …
Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: a systematic review comparing benefits and harms between observational …
NN Shen, Y Wu, N Wang, LC Kong, C Zhang… - Frontiers in …, 2020 - frontiersin.org
Background: The publication of high-quality observational studies (OSs) has fueled
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …
New oral anticoagulants for venous thromboembolism prophylaxis in total hip and knee arthroplasty: a systematic review and network meta-analysis
Y Yi, S Gong, T Gong, L Zhou, C Hu… - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: There is controversy over whether use of new oral anticoagulants (NOACs)
associates with increased hemorrhage risk compared with non-NOAC. Meanwhile …
associates with increased hemorrhage risk compared with non-NOAC. Meanwhile …
[HTML][HTML] Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III …
ZC Gu, LC Kong, SF Yang, AH Wei… - Cardiovascular …, 2019 - ncbi.nlm.nih.gov
Background Atrial fibrillation (AF) is quite prevalent in patient with chronic kidney disease
(CKD). This study mainly investigated the net clinical benefit (NCB) property of non-vitamin K …
(CKD). This study mainly investigated the net clinical benefit (NCB) property of non-vitamin K …
Comparative effectiveness and safety of direct oral anticoagulants: overview of systematic reviews
Direct oral anticoagulants are now recommended by major guidelines as first-choice agents
for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of …
for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of …
Noncanonical effects of oral thrombin and factor Xa inhibitors in platelet activation and arterial thrombosis
A Polzin, L Dannenberg, M Thienel… - Thrombosis and …, 2021 - thieme-connect.com
Nonvitamin K oral anticoagulants (NOACs) or direct oral anticoagulants comprise inhibitors
of factor Xa (rivaroxaban, apixaban, edoxaban) or factor IIa (dabigatran). Both classes …
of factor Xa (rivaroxaban, apixaban, edoxaban) or factor IIa (dabigatran). Both classes …
[HTML][HTML] A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension
YJ Zhang, N Wang, ZC Gu, AH Wei… - Cardiovascular …, 2019 - ncbi.nlm.nih.gov
Background Currently, direct comparative safety between endothelin receptor antagonists
(ERAs) in pulmonary arterial hypertension (PAH) is limited. Thus, a systematic review with …
(ERAs) in pulmonary arterial hypertension (PAH) is limited. Thus, a systematic review with …